10x genomics inc TXG.US 總覽分析
TXG 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分低，若以價值投資為目標且有長期投資部位，需要嚴格執行自己的出場計畫來減持部位
TXG 近期報酬表現
3.90%
10x genomics inc
2.24%
同產業平均
0.40%
S&P500
與 TXG 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
ADPT | Adaptive biotechnologies corp | 4 分 | 4 分 | 3 分 | 2 分 | 1 分 | |
PACB | Pacific biosciences of california inc | 2 分 | 3 分 | 2 分 | 1 分 | 1 分 | |
VCYT | Veracyte inc | 4 分 | 5 分 | 3 分 | 3 分 | 1 分 | |
TWST | Twist bioscience corp | 3 分 | 3 分 | 3 分 | 2 分 | 1 分 | |
DNLI | Denali therapeutics inc | 4 分 | 3 分 | 2 分 | 3 分 | 1 分 |
- ADPT Adaptive biotechnologies corp價值 4 分趨勢 4 分波段 3 分籌碼 2 分股利 1 分查看更多
TXG 公司資訊
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.